Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Neoplasms × Dexmedetomidine × Clear all

Phase

Status

Completed 4 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 5 Pituitary Neoplasms 3 Brain Neoplasms 3 Stomach Neoplasms 2 Pain 2 Delirium 2 Breast Neoplasms 2 Supratentorial Neoplasms 1 Spinal Cord Neoplasms 1 Sleep Deprivation 1 Retinoblastoma 1 Pituitary Diseases 1 Non-functioning Pituitary Adenoma 1 Neoplasms 1 Morphine Consumption 1 Lung Neoplasms 1 Intrathecal Dexmedetomidine 1 Intracranial Aneurysm 1 Intestinal Obstruction 1 Intestinal Fistula 1 Inflammation 1 Immune System Suppression 1 Hyperparathyroidism 1 Fibrosis 1 Female Patients Under the Age of 65 Who Will Undergo Breast Cancer Surgery 1 Cough 1 Colorectal Neoplasms 1 Central Nervous System Diseases 1 Breast Cancer Patients 1 Agnosia 1

Interventions

Exercise 18 Drug Therapy 16 pembrolizumab 11 Surveys and Questionnaires 11 Capecitabine 11 Blood Specimen Collection 11 Radiotherapy 10 Dexamethasone 9 Paclitaxel 8 Standard of Care 7 Oxaliplatin 7 Nivolumab 7 Fluorouracil 7 Erlotinib Hydrochloride 7 apatinib 6 Interviews as Topic 6 Gemcitabine 6 Cisplatin 6 Therapeutics 5 Neoadjuvant Therapy 5 Mindfulness-Based Cognitive Therapy 5 Metformin 5 Injections 5 Everolimus 5 Docetaxel 5 Cyclophosphamide 5 Control Groups 5 Biopsy 5 Bevacizumab 5 sintilimab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04106999 2022-11-03

Dexmedetomidine and HIPEC

University of British Columbia

Phase 2/3 Unknown

Inflammation, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡